Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited disclaim responsibility for the contents of the announcement of Cloudbreak Pharma Inc. (the “Company”), make no representation as to its accuracy or completeness, and expressly disclaim any liability for any loss arising from or in reliance upon its content.

Cloudbreak Pharma Inc. (Stock Code: 2592), together with its subsidiaries (“the Group”), issued an inside information announcement regarding the settlement of proceedings. The Company referred to previous announcements dated 7 January 2026 and 15 January 2026, which disclosed proceedings and a settlement agreement involving the Company, Cloudbreak Guangzhou, and Cedar Wealth. Under the agreement, Cedar Wealth is to submit applications for the lifting of an asset preservation order and the withdrawal of the arbitration proceedings upon receipt of the settlement sum.

According to a notice of decision dated 23 January 2026 from the Shanwei Arbitration Commission, received by the Company and Cloudbreak Guangzhou on 28 January 2026, the withdrawal application filed by Cedar Wealth has been approved. All arbitration fees related to these proceedings are to be borne by Cedar Wealth.

Further announcements will be made to keep shareholders and potential investors informed of the latest developments in accordance with the Listing Rules. Shareholders and potential investors are advised to exercise caution when dealing in the Company’s securities.

By order of the Board, dated 29 January 2026, the Company’s Chairman of the Board, Executive Director, and Chief Executive Officer, Dr. Ni Jinsong, stated that, as of the date of the announcement, the board of directors comprises Dr. Ni Jinsong, Mr. Dinh Son Van, and Dr. Yang Rong as executive directors; Dr. Li Jun Zhi, Mr. Cao Xu, and Mr. Xia Zhidong as non-executive directors; and Ms. Nie Sijiang, Mr. Ma Yiu Ho Peter, and Mr. Lee Alex Jao Jang as independent non-executive directors.